4 Lots of Generic Zyrtec Recalled Over Cross-Contamination Risk

For biopharma professionals, the recall of four lots of generic cetirizine by an Indian manufacturer’s U.S. arm is more than a routine consumer alert — it’s a stress test of outsourcing quality systems. The misprinting of tablet identifiers signals a breakdown in line clearance or labeling, fundamental CGMP processes that, when they fail, can expose distributors and patients to unknown active pharmaceutical ingredients with life-threatening potential.

In late July 2026, the U.S. Food and Drug Administration (FDA) disclosed a voluntary recall of four lots of over-the-counter cetirizine hydrochloride tablets manufactured by Unique Pharmaceutical Laboratories, a U.S.-based division of India's J.B. Chemicals & Pharmaceuticals Ltd. The recall, initiated on September 19, 2025, stemmed from a manufacturing anomaly in which some tablets were imprinted with the wrong identifier, signaling potential cross-contamination with an undisclosed different medication. The affected 100-tablet bottles were distributed nationwide by Rising Pharma Holdings Inc., of East Brunswick, New Jersey. No adverse events had been reported as of the recall notice, and the FDA classified the action as Class III — a situation in which exposure is unlikely to cause adverse health consequences, underscoring a low probability of serious harm despite the theoretical risk of life-threatening reactions for certain consumers.

“

OTC allergy market valued at over $8 billion annually, and cetirizine representing a substantial generic segment, any manufacturing misstep carries outsized implications for consumer trust and manufacturer liability.

The recall spotlights persistent quality-control challenges in the global generic-drug supply chain, particularly for widely used OTC antihistamines like cetirizine, the active ingredient in branded Zyrtec. With the U.S. OTC allergy market valued at over $8 billion annually, and cetirizine representing a substantial generic segment, any manufacturing misstep carries outsized implications for consumer trust and manufacturer liability. Unique Pharmaceutical Laboratories operates as a contract manufacturer for multiple distributors; the cross-contamination episode illustrates how a single deviation in tablet identification or line clearance can cascade into a nationwide recall. The fact that the recall was voluntary, and that the FDA assigned the lowest-risk classification, suggests that the company's subsequent investigation and remediation met regulatory expectations. However, the agency's notice emphasized that the foreign tablet markings indicated presence of a different medication entirely — a grave error in pharmaceutical production that could, in a worst-case scenario, cause life-threatening allergic reactions, cardiac events, or dangerous drug interactions in unsuspecting patients.

From a regulatory standpoint, the Class III designation is somewhat ambiguous. While it indicates a low probability of adverse health consequences, the FDA’s own definition allows for situations where a product may cause temporary or medically reversible health consequences, or where the probability of serious adverse health consequences is remote. The juxtaposition of 'life-threatening' and 'Class III' in the same notice hints that the contaminating medication, though potent for a narrow sub-population, may be present in such minuscule quantities or be so rarely dispensed from the affected lots that the overall risk is negligible. This nuanced risk calculus is precisely what the FDA's recall classifications are designed to capture, balancing public health prudence against the practicalities of supply-chain disruption and product shortage risks. For J.B. Chemicals, which derives a significant share of its revenue from export formulations, even a Class III recall can ripple through investor sentiment and future business with U.S. distributors, particularly if it triggers a deeper FDA for-cause inspection of the Mumbai-based parent’s manufacturing sites.